Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning
- PMID: 16905365
- DOI: 10.1016/j.ymthe.2006.06.007
Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning
Abstract
Gene therapy is a promising treatment option for monogenic diseases, but success has been seen in only a handful of studies thus far. We now document successful reconstitution of immune function in a child with the adenosine deaminase (ADA)-deficient form of severe combined immunodeficiency (SCID) following hematopoietic stem cell (HSC) gene therapy. An ADA-SCID child who showed a poor response to PEG-ADA enzyme replacement was enrolled into the clinical study. Following cessation of enzyme replacement therapy, autologous CD34(+) HSCs were transduced with an ADA-expressing gammaretroviral vector. Gene-modified cells were reinfused following one dose of preconditioning chemotherapy. Two years after the procedure, immunological and biochemical correction has been maintained with progressive increase in lymphocyte numbers, reinitiation of thymopoiesis, and systemic detoxification of ADA metabolites. Sustained vector marking with detection of polyclonal vector integration sites in multiple cell lineages and detection of ADA activity in red blood cells suggests transduction of early hematopoietic progenitors. No serious side effects were seen either as a result of the conditioning procedure or due to retroviral insertion. Gene therapy is an effective treatment option for the treatment of ADA-SCID.
Similar articles
-
Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.IDrugs. 2006 Jun;9(6):423-30. IDrugs. 2006. PMID: 16752313
-
[Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].Med Wieku Rozwoj. 2003 Jan-Mar;7(1):27-34. Med Wieku Rozwoj. 2003. PMID: 13130167 Review. Polish.
-
Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.Hum Gene Ther. 1993 Aug;4(4):521-7. doi: 10.1089/hum.1993.4.4-521. Hum Gene Ther. 1993. PMID: 7691188
-
Bone marrow gene transfer in three patients with adenosine deaminase deficiency.Gene Ther. 1996 Feb;3(2):179-83. Gene Ther. 1996. PMID: 8867866
-
Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.Semin Hematol. 1998 Oct;35(4):291-8. Semin Hematol. 1998. PMID: 9801258 Review.
Cited by
-
The hyper IgM syndromes.Clin Rev Allergy Immunol. 2014 Apr;46(2):120-30. doi: 10.1007/s12016-013-8378-7. Clin Rev Allergy Immunol. 2014. PMID: 23797640 Review.
-
The β-globin locus control region in combination with the EF1α short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity.Mol Ther. 2012 Jul;20(7):1400-9. doi: 10.1038/mt.2012.50. Epub 2012 Mar 20. Mol Ther. 2012. PMID: 22434141 Free PMC article.
-
Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).Biologics. 2009;3:349-58. Epub 2009 Jul 13. Biologics. 2009. PMID: 19707420 Free PMC article.
-
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.J Clin Invest. 2007 Aug;117(8):2241-9. doi: 10.1172/JCI31661. J Clin Invest. 2007. PMID: 17671654 Free PMC article. Clinical Trial.
-
Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.Immunol Res. 2009;44(1-3):150-9. doi: 10.1007/s12026-009-8107-8. Immunol Res. 2009. PMID: 19224139
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
